PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
68.7 ^USD	+0.88%		+8.19%	+63.92%

May. 15	Transcript : PROCEPT BioRobotics Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
May. 06	Piper Sandler Adjusts Price Target on PROCEPT BioRobotics to $75 From $67, Maintains Overweight Rating	MT

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

May 01, 2024 at 07:00 am EDT

PROCEPT BioRobotics Corporation increased revenue guidance for full year 2024. For the period, the Company projects revenue for the full year 2024 to be $213.5 million, which represents 57% growth over the Company?s prior year revenue. This compares to previous revenue guidance of $210.0 million.

Latest news about PROCEPT BioRobotics Corporation

Transcript : PROCEPT BioRobotics Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM	May. 15
Piper Sandler Adjusts Price Target on PROCEPT BioRobotics to $75 From $67, Maintains Overweight Rating	May. 06	MT
PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia	May. 06	CI
Procept BioRobotics Insider Sold Shares Worth $1,200,000, According to a Recent SEC Filing	May. 06	MT
Procept BioRobotics Insider Sold Shares Worth $1,916,428, According to a Recent SEC Filing	May. 06	MT
Transcript : PROCEPT BioRobotics Corporation - Analyst/Investor Day	May. 03
Truist Raises PROCEPT BioRobotics' PT to $72 From $63 After 'Solid' Q1 Beat, Keeps Buy Rating	May. 02	MT
Procept BioRobotics Shares Rise After Q1 Loss Narrows, Revenue Increases; 2024 Revenue Guidance Revised	May. 01	MT
Transcript : PROCEPT BioRobotics Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
PROCEPT BioRobotics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Reports Q1 Revenue $44.5M, vs. Street Est of $41.7M	May. 01	MT
Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024	May. 01	CI
PROCEPT BioRobotics Corporation Announces Board and Committee Changes	Apr. 19	CI
Procept Biorobotics Insider Sold Shares Worth $263,243, According to a Recent SEC Filing	Mar. 21	MT
Procept Biorobotics Insider Sold Shares Worth $428,384, According to a Recent SEC Filing	Mar. 08	MT
Procept Biorobotics Insider Sold Shares Worth $970,643, According to a Recent SEC Filing	Mar. 06	MT
PROCEPT BioRobotics Q4 Net Loss Narrows as Revenue Increases	Feb. 28	MT
Transcript : PROCEPT BioRobotics Corporation, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Posts Q4 Revenue $43.6M, vs. Street Est of $41.9M	Feb. 27	MT
PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 27	CI
PROCEPT BioRobotics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Procept Biorobotics Insider Sold Shares Worth $1,121,062, According to a Recent SEC Filing	Feb. 13	MT
Procept Biorobotics Insider Sold Shares Worth $1,481,579, According to a Recent SEC Filing	Feb. 09	MT
Procept Biorobotics Insider Sold Shares Worth $999,367, According to a Recent SEC Filing	Feb. 09	MT
Procept Biorobotics Insider Sold Shares Worth $719,475, According to a Recent SEC Filing	Jan. 11	MT

Chart PROCEPT BioRobotics Corporation

Duration

Period

More charts

Company Profile

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Leerink Partners Healthcare Crossroads Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for PROCEPT BioRobotics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

68.7 USD

Average target price

72.17 USD

Spread / Average Target

+5.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PROCEPT BIOROBOTICS CORPORATION	+63.92%	3.5B
ABBOTT LABORATORIES	-6.23%	181B
MEDTRONIC PLC	+2.59%	114B
BECTON, DICKINSON AND COMPANY	-2.75%	68.29B
DEXCOM, INC.	+5.32%	52.24B
CENCORA, INC.	+7.61%	44.3B
HOYA CORPORATION	+5.28%	42.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.17%	32.52B
TERUMO CORPORATION	+17.50%	26.02B
WEST PHARMACEUTICAL SERVICES, INC.	-2.66%	25.91B

Other Medical Equipment, Supplies & Distribution